Regulatory Role of m6A Epitranscriptomics in Immune Responses and Autoimmune Conditions
Overview
This review discusses the role of N6-methyladenosine (m6A) RNA methylation in immune cell function and autoimmune diseases. It highlights the regulatory mechanisms of m6A, including its writers, erasers, and readers, and emerging therapeutic strategies targeting these regulators, such as METTL3 inhibition for Th17-driven multiple sclerosis and rheumatoid arthritis synovitis.
Background
Autoimmune diseases (ADs) affect nearly 10% of the global population and arise from complex interactions among genetic, environmental, and epigenetic factors. Recent research has shifted focus towards RNA epigenetics, particularly m6A methylation, which plays a critical role in regulating immune responses and maintaining immune homeostasis. Understanding m6A's role in autoimmunity is essential for developing targeted therapies that address the dysregulation of immune responses.
Data Highlights
No numerical data or trial data provided in the source material.
Key Findings
m6A RNA methylation is a key post-transcriptional regulator of immune cell function.
m6A regulators include writers (METTL3/14), erasers (FTO, ALKBH5), and readers (YTHDF1–3, IGF2BP3).
Dysregulated m6A signaling is implicated in the pathogenesis of various autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Therapeutic strategies targeting m6A regulators, such as METTL3 inhibition, show promise in conditions like Th17-driven multiple sclerosis and RA synovitis.
Challenges remain in targeting specific immune subsets and ensuring the long-term safety of epitranscriptomic drugs.
Clinical Implications
m6A regulators could serve as potential therapeutic targets in autoimmune diseases. Clinicians should be aware of the evolving landscape of epitranscriptomic therapies as they relate to precision medicine.
Conclusion
m6A RNA methylation plays a significant role in immune regulation and autoimmune disease progression, indicating the need for further research into its therapeutic potential.
